Journal of Clinical Oncology
Articles in this Issue
Molecular predictors of local recurrence after CRT and surgery in locally advanced rectal cancer.
222 Background: Colorectal cancer is the second leading cause of cancer death in the US, with the incidence rising, especi...
Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).
561 Background: For patients with aHCC, second-line treatment options are not well established. The primary aim of this st...
Safety and efficacy of zolbetuximab plus chemotherapy for CLDN18.2-positive gastric cancer: A single-center retrospective study.
308 Background: The GLOW and SPOTLIGHT trials demonstrated that adding zolbetuximab (ZOL) to chemotherapy significantly im...
Phase II study of NALIRIFOX (nanoliposomal irinotecan + oxaliplatin with fluorouracil and folinic acid) in advanced unresectable small bowel tumors.
TPS802 Background: Small bowel cancers account for 3% of all gastrointestinal malignancies and small bowel adenocarcinoma...
Age-based outcomes and patterns of care of patients with metastatic pancreatic cancer: An updated comparative analysis from Fox Chase Cancer Center.
668 Background: Prior analysis of patients with metastatic pancreatic cancer (mPC) treated at Fox Chase Cancer Center (FCC...
A comparative analysis of colorectal cancer in high-income North America vs Asian subregions: Temporal trends, age patterns, gender and risk-factor disparities using GBD 2021.
84 Background: Colorectal cancer (CRC) burdens vary across North America and Asia due to screening, diet, and metabolic ri...
Transcriptomic profiling and demographic analysis of Appalachian and non-Appalachian patients with pancreatic ductal adenocarcinoma using the Purity Independent Subtyping of Tumors Classifier.
752 Background: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with poor prognosis. A transcriptomic based...
Adjuvant sintilimab plus capecitabine in resected extrahepatic cholangiocarcinoma: Interim report of a single-arm, prospective phase II study.
557 Background: The efficacy of adjuvant chemotherapy alone in extrahepatic cholangiocarcinoma (EHC) remains limited, with...
Mapping preventable risks: Obesity, alcohol, and hepatocellular carcinoma in the U.S.
528 Background: Hepatocellular carcinoma (HCC) is a major public health concern in the U.S., with obesity and alcohol cons...
ERBB2/HER2 status in biliary tract cancer patients in the Spanish RETUD registry.
498 Background: ERBB2 gene amplification or HER2 receptor overexpression is a well-known oncogenic driver and represents a...
Safety and tolerability of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer.
114 Background: Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) demonstrates limited response to immunothe...
Treatment patterns and survival outcomes in Klatskin tumors: A real-world analysis of the TriNetX network.
513 Background: Klatskin tumors (perihilar cholangiocarcinoma) are rare biliary tract malignancies with poor prognosis. Su...
A phase II study of nanoliposomal irinotecan with TAS102 and bevacizumab for patients with refractory metastatic colorectal cancer (mCRC).
161 Background: Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related death. The combination of triflur...
A phase I first in human, open-label, multicenter study of BI3706674, KRAS multi-inhibitor, monotherapy in patients with advanced solid tumors bearing KRAS WT amp.
380 Background: KRAS amplifications (amp) occur in ~2% of solid tumors, representing a high unmet need for effective targe...
Preclinical rationale for FGFR1 blockade in colorectal cancer.
164 Background: Aberrant activation of fibroblast growth factor receptor (FGFR) pathways contributes to tumor progression...
Descriptive analysis of outcomes in participants with combined hepatocellular-cholangiocarcinoma in the phase 3 KEYNOTE-966 trial.
563 Background: In the phase 3 KEYNOTE-966 trial (NCT04003636), pembrolizumab (pembro) plus gemcitabine and cisplatin (gem...
Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with <i>KRAS G12D</i> -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights.
775 Background: KRAS G12D is a critical oncogenic driver and a high-priority therapeutic target in PDA...
Use of transcriptomic signatures of <i>RAD51</i> and <i>GATA6</i> to predict real-world overall survival with platinum therapy in <i>BRCA/PALB2</i> wild-type metastatic pancreatic cancer.
679 Background: DNA-damaging agents improve outcomes in metastatic pancreatic cancer (mPC) with homologous recombination r...
A phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treated unresectable hepatocellular carcinoma.
TPS611 Background: GPC3 is an oncofetal protein expressed in up to 75% of hepatocellular carcinomas (HCCs) and associated...
Inpatient palliative care and clinical outcomes in gastric cancer with sepsis: A population-based cohort study.
340 Background: Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer-related death wo...
Effect of surgeon specialty and health system characteristics on outcomes after pancreatic adenocarcinoma resection.
663 Background: Outcomes for pancreatic adenocarcinoma patients have improved with multidisciplinary care and centralizati...
Survival outcomes in patients (pts) with Child-Pugh class B (CP-B) liver function at progression after first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable hepatocellular carcinoma (uHCC): Asia-Pacific multicenter retrospective analysis.
553 Background: Worsening liver function is a major challenge in the management of uHCC. The optimal subsequent treatment...
Readability and quality of information of AI-generated patient education materials on familial adenomatous polyposis.
240 Background: Artificial intelligence (AI) and large language model (LLM) chatbots are increasingly consulted by patient...
Non-invasive early detection of gastric cancer using red blood cell DNA genomic signature: A multi-center validation study.
452 Background: Early detection of gastric cancer (GC) is critical for improving survival but remains challenged by the in...
Claudin-18.2 and Trop-2 as emerging biomarkers in biliary tract cancers: Expression analysis and therapeutic potential.
590 Background: Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder carcinoma, are aggressive tumors...